In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of SAB Biotherapeutics Inc (NASDAQ: SABS) was $2.95 for the day, down -0.67% from the previous closing price of $2.97. In other words, the price has decreased by -$0.67 from its previous closing price. On the day, 89459.0 shares were traded. SABS stock price reached its highest trading level at $3.095 during the session, while it also had its lowest trading level at $2.85.
Ratios:
Our analysis of SABS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.69 and its Current Ratio is at 3.69. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on October 09, 2024, initiated with a Buy rating and assigned the stock a target price of $11.
On August 28, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $12.
On November 05, 2021, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $17.Chardan Capital Markets initiated its Buy rating on November 05, 2021, with a $17 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 07 ’23 when Sullivan Eddie Joe bought 1,740 shares for $0.88 per share. The transaction valued at 1,531 led to the insider holds 5,232,304 shares of the business.
King Michael bought 5,000 shares of SABS for $4,500 on Nov 30 ’23. The CHIEF FINANCIAL OFFICER now owns 5,000 shares after completing the transaction at $0.90 per share. On Nov 29 ’23, another insider, Reich Samuel J, who serves as the Executive Chairman of the company, bought 11,000 shares for $0.89 each. As a result, the insider paid 9,842 and bolstered with 219,001 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SABS now has a Market Capitalization of 27226346 and an Enterprise Value of 1345975. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.03 while its Price-to-Book (P/B) ratio in mrq is 0.74. Its current Enterprise Value per Revenue stands at 0.89 whereas that against EBITDA is -0.029.
Stock Price History:
Over the past 52 weeks, SABS has reached a high of $9.72, while it has fallen to a 52-week low of $2.16. The 50-Day Moving Average of the stock is -1.73%, while the 200-Day Moving Average is calculated to be -14.72%.
Shares Statistics:
SABS traded an average of 74.72K shares per day over the past three months and 73450 shares per day over the past ten days. A total of 9.23M shares are outstanding, with a floating share count of 7.49M. Insiders hold about 18.88% of the company’s shares, while institutions hold 34.25% stake in the company. Shares short for SABS as of 1731628800 were 39930 with a Short Ratio of 0.53, compared to 1728950400 on 79819. Therefore, it implies a Short% of Shares Outstanding of 39930 and a Short% of Float of 0.5700000000000001.
